Botanix Investor Centre
Botanix Pharmaceuticals is a clinical stage dermatology company developing novel treatments for common skin diseases and infection leveraging its novel delivery technology, Permetrex™.
Our goal is to unlock the true potential of synthetic cannabinoids for people around the world, with an evidence-first approach. Our shareholders are valued partners in our Company, so we invite you to explore our Investor Centre, subscribe to our email updates and we will keep you updated with our progress.
ASX: BOT | Share price
Change
ASX Releases
Analyst Reports
Aug 9, 2021
Feb 4, 2021
Mar 16, 2020
Feb 3, 2020
Oct 24, 2019
Oct 23, 2019
June 18, 2019
Nov 21, 2018
Nov 21, 2018
July 20, 2018
January 30, 2018
November 3, 2017
August 21, 2017
August 17, 2017
May 9, 2017
April 21, 2017
April 6, 2017
March 22, 2017
Corporate governance
Investor Services
Presentations
September 8, 2020
January 13, 2020
December 9, 2019
November 21, 2019
October 28, 2019
October 23, 2019
September 17, 2019
September 13, 2019
June 24, 2019
January 31, 2019
December 14, 2018
December 5, 2018
November 15, 2018
October 19, 2018
September 13, 2018
August 13, 2018
July 2, 2018
April 9, 2018
February 15, 2018
January 22, 2018
January 7, 2018
November 13, 2017
July 11, 2017
May 4, 2017
April 5, 2017
March 22, 2017
